Clinical Trial News and Research

RSS

CTT, Bayer sign Research and License Option Agreement

Cancer Targeted Technology (CTT), a Seattle-based biotechnology firm focusing on small molecule cancer enzyme inhibitors for the generation of novel diagnostics and therapeutics, today announced that it has signed a Research and License Option Agreement with Bayer Pharma AG, Germany. Under the agreement, CTT will work with Bayer to optimize a novel PET imaging agent based on its unique inhibitor scaffold that recognizes a validated cancer enzyme biomarker.

15 Dec 2010

MHRA issues notice of acceptance for BioMarin's GALNS Phase 3 trial in MPS IVA

BioMarin Pharmaceutical Inc. today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application (CTA) and issued a notice of acceptance for the Phase 3 trial of N-acetylgalactosamine 6-sulfatase (GALNS) for the treatment of Mucopolysaccharidosis IVA (MPS IVA). The company expects to initiate the Phase 3 pivotal trial early in the first quarter of 2011.

15 Dec 2010

Positive results from large, multi-center Canadian trial with On-X Prosthetic Heart Valve

On-X® Life Technologies, Inc., today announced the publication of results of a large, prospective multi-center Canadian trial with the On-X® Prosthetic Heart Valve in the November issue of The Journal of Thoracic and Cardiovascular Surgery.1 According to the results of the report, "The On-X mechanical prosthesis provides favorable intermediate-term results with regard to major thromboembolism, hemorrhage and composites of valve-related complications."

15 Dec 2010

Study broadens understanding of role of IDH1 and IDH2 mutations in AML

Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, today announced the publication of a paper in Cancer Cell that illuminates the mechanism by which 2-hydroxyglutarate (2HG), and the mutations in the metabolic genes IDH1 and IDH2 that produce it, may be driving the growth of tumors in patients with acute myeloid leukemia (AML).

15 Dec 2010

NCI initiates crolibulin/cisplatin combination Phase II trial in anaplastic thyroid cancer

EpiCept Corporation today announced that the National Cancer Institute (NCI) has initiated a Phase II trial with crolibulinTM (EPC2407). The trial will assess the drug's efficacy and safety in combination with cisplatin in patients with anaplastic thyroid cancer (ATC). CrolibulinTM is a vascular disruption and apoptosis inducing agent that has demonstrated potent anti-tumor activity in both preclinical and early clinical studies.

15 Dec 2010

CRI introduces new model of philanthropic investment to improve cancer patient care

Cancer Research Institute, Inc. (CRI), a U.S. nonprofit organization established in 1953 to advance the science of tumor immunology and foster the discovery of new cancer immunotherapies, announced today the launch of the Cancer Vaccine Acceleration Fund (CVAF), a new model of philanthropic investment and academic-industry collaboration established in partnership with the Ludwig Institute for Cancer Research Ltd (LICR) to speed the clinical development of therapeutic cancer vaccines and other immune system-based therapies.

15 Dec 2010

Lung protective strategy can increase the number of lungs available for transplant

Simple changes to how ventilators are used could almost double the number of lungs available for transplants, according to new international research involving a doctor at St. Michael's Hospital.

15 Dec 2010

MVI, Merck and NYU collaborate to research potential malaria vaccine

Development of a vaccine to prevent the malaria parasite from entering the human liver is the goal of a new collaboration announced today by global leaders in malaria research and vaccine development. The PATH Malaria Vaccine Initiative (MVI), Merck (known outside the US and Canada as MSD), and NYU Langone Medical Center are working together to evaluate an approach targeting a novel part of a major surface protein on the malaria parasite. Malaria is estimated to kill close to 900,000 people each year with the majority of deaths occurring in children under the age of five in sub-Saharan Africa.

14 Dec 2010

Tolerx commences TRX518 Phase 1 trial in malignant melanoma

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced that it has initiated a Phase 1 clinical trial to assess the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of TRX518, a monoclonal antibody designed to enhance the immune system by enabling T cells to more effectively attack cancer cells.

14 Dec 2010

Provectus commences PH-10 Phase 2c trial for psoriasis

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 2c clinical trial of PH-10 for psoriasis. This multicenter, randomized controlled Phase 2c study is expected to enroll up to 90 subjects at four different sites, beginning in late December.

14 Dec 2010

Clinical trial investigates pomalidomide in only U.S. study for multiple myeloma

Multiple myeloma, a type of blood cancer in which malignant plasma cells are overproduced in the bone marrow, has led to an estimated 20,000 new diagnoses and 11,000 deaths in 2010. Patients with the disease, who have already failed previous treatments, may be considered for a currently enrolling Phase II study, examining a unique drug combination.

14 Dec 2010

Myths and misunderstandings about medical male circumcision for HIV prevention

A new report from the Women's HIV Prevention Tracking Project (WHiPT), a collaborative initiative of AVAC and the ATHENA Network, features an unprecedented collection of voices from Kenya, Namibia, South Africa, Swaziland and Uganda reflecting on what male circumcision for HIV prevention means for women. It highlights women's perspectives, advocacy priorities and recommendations on this new prevention strategy.

14 Dec 2010

New collaboration to develop vaccine to prevent malaria parasite from entering human liver

14 Dec 2010

GTx announces Capesaris proof of concept clinical trail in men with advanced prostate cancer

BETHESDA, Md.,GTx, Inc. this weekend presented results of the Capesaris™ (GTx-758) proof of concept pharmacokinetic-pharmacodynamic (PK/PD) clinical trial at the Annual Meeting of the Society of Urologic Oncology.

14 Dec 2010

Chimerix reports positive results from CMX157 Phase 1 clinical trial for HIV

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced first-in-human Phase 1 clinical trial results for CMX157 demonstrating a favorable safety, tolerability and drug distribution profile.

14 Dec 2010

Clinical trail shows 2009 H1N1 influenza vaccine safe and effective in asthma patients

Results from a government-sponsored clinical trial of inactivated 2009 H1N1 influenza vaccine in people with asthma indicate that a single dose of vaccine was safe and induced a strong immune response predictive of protection.

14 Dec 2010

Reversible two-step binding mechanism to stop cancer cell growth

What makes cancer cells so dangerous is that they grow in an unregulated way and proliferate much faster than other cells. The proteasome, a large protein complex, plays a key role in this process: By breaking down used proteins for recycling, it clears the way for the next cycle.

14 Dec 2010

Top-line results from Inhibitex's FV-100 Phase II clinical trial for treatment of shingles

Inhibitex, Inc. today reported top-line safety and efficacy data from its Phase II clinical trial of FV-100, an oral antiviral compound being developed to treat herpes zoster, more commonly referred to as shingles. The study was the first clinical trial to assess the antiviral activity of FV-100, included 350 shingles patients and compared two once-daily doses of FV-100 (200 mg and 400 mg) to an active control, valacyclovir, one of the most commonly-used antiviral drugs to treat shingles.

14 Dec 2010

Capstone presents AZX100 Phase 2a trial results for keloid and trocar site scarring

Capstone Therapeutics announced today twelve-month results from its two AZX100 Phase 2a pilot clinical trials in keloid scarring and seven-month interim results of its ongoing AZX100 Phase 2a pilot clinical trial in surgical (trocar site) scarring.

14 Dec 2010

Lilly suspends tasisulam global Phase III study in metastatic melanoma

Eli Lilly and Company announced today that it has suspended its global Phase III study evaluating tasisulam, an investigational, small-molecule anti-cancer compound, as a second-line treatment for those with unresectable or metastatic melanoma.

13 Dec 2010

Clinical Trial News and Research

CTT, Bayer sign Research and License Option Agreement

MHRA issues notice of acceptance for BioMarin's GALNS Phase 3 trial in MPS IVA

Positive results from large, multi-center Canadian trial with On-X Prosthetic Heart Valve

Study broadens understanding of role of IDH1 and IDH2 mutations in AML

NCI initiates crolibulin/cisplatin combination Phase II trial in anaplastic thyroid cancer

CRI introduces new model of philanthropic investment to improve cancer patient care

Lung protective strategy can increase the number of lungs available for transplant

MVI, Merck and NYU collaborate to research potential malaria vaccine

Tolerx commences TRX518 Phase 1 trial in malignant melanoma

Provectus commences PH-10 Phase 2c trial for psoriasis

Clinical trial investigates pomalidomide in only U.S. study for multiple myeloma

Myths and misunderstandings about medical male circumcision for HIV prevention

New collaboration to develop vaccine to prevent malaria parasite from entering human liver

GTx announces Capesaris proof of concept clinical trail in men with advanced prostate cancer

Chimerix reports positive results from CMX157 Phase 1 clinical trial for HIV

Clinical trail shows 2009 H1N1 influenza vaccine safe and effective in asthma patients

Reversible two-step binding mechanism to stop cancer cell growth

Top-line results from Inhibitex's FV-100 Phase II clinical trial for treatment of shingles

Capstone presents AZX100 Phase 2a trial results for keloid and trocar site scarring

Lilly suspends tasisulam global Phase III study in metastatic melanoma

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News